Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 3Phase EARLY_PHASE1 1

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 73Sarcoma 9Thoracic 3Gynecologic 3Genitourinary 3Head & Neck 2CNS 2Tumor-Agnostic 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1

Interventions

Paclitaxel 233Carboplatin 217Bevacizumab 139Cisplatin 136pembrolizumab 89Gemcitabine 69olaparib 54Docetaxel 47Topotecan 44Radiotherapy 43liposomal doxorubicin 41Taxes 41niraparib 38Cyclophosphamide 36Doxorubicin 30Drug Therapy 29Letrozole 28Nivolumab 27Magnetic Resonance Spectroscopy 25Immunoglobulin G 25Disulfides 24Oxaliplatin 23Albumin-Bound Paclitaxel 23durvalumab 22apatinib 21Etoposide 21Brachytherapy 21lenvatinib 20camrelizumab 20Specimen Handling 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × eribulin × Gynecologic × Clear all
NCT01676818 2025-11-06

Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer

University of Southern California

Phase 2 Completed
32 enrolled 17 charts
Gynecologic

Uterine Cervical Neoplasms

NCT00334893 2017-11-29

Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 2 Completed
74 enrolled 7 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT03032614 2017-10-10

Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients

The University of Texas Health Science Center at San Antonio

Phase 2 Withdrawn
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡